Autosomal Dominant Polycystic Kidney Disease
52
7
11
30
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
11 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.8%
2 terminated out of 52 trials
93.8%
+7.2% vs benchmark
12%
6 trials in Phase 3/4
37%
11 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (52)
Renal Denervation in ADPKD- RDN-ADPKD Study
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository
Intrarenal Microvasculature in ADPKD
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NOX4 and Related Biomarkers in ADPKD
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD
National Registry of Rare Kidney Diseases
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Tolvaptan-Octreotide LAR Combination in ADPKD